Marsicano G: Difference between revisions
From Bioblast
(Created page with "{{Person}}") |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Person}} | {{Person | ||
|lastname=Marsicano | |||
|firstname=Giovanni | |||
|title=DVM, PhD | |||
|institution=Giovanni Marsicano DVM, PhD | |||
NeuroCentre Magendie | |||
U862 INSERM Université Bordeaux 2 | |||
Group "Endocannabinoids and Neuroadaptation" | |||
|address=146, rue Léo Saignat | |||
|area code=33077 | |||
|city=Bordeaux | |||
|country=France | |||
|mailaddress=giovanni.marsicano@gmail.com | |||
}} | |||
{{Labelingperson}} | |||
Revision as of 09:06, 2 May 2016
| Name | Marsicano Giovanni, DVM, PhD |
|---|---|
| Institution | Giovanni Marsicano DVM, PhD
NeuroCentre Magendie U862 INSERM Université Bordeaux 2 Group "Endocannabinoids and Neuroadaptation" |
| Address | 146, rue Léo Saignat, 33077 |
| City | Bordeaux |
| State/Province | |
| Country | France |
| giovanni.marsicano@gmail.com | |
| Weblink | |
| O2k-Network Lab |
Labels:
Publications
| Published | Reference | |
|---|---|---|
| Haney 2023 Nat Med | 2023 | Haney M, Vallée M, Fabre S, Collins Reed S, Zanese M, Campistron G, Arout CA, Foltin RW, Cooper ZD, Kearney-Ramos T, Metna M, Justinova Z, Schindler C, Hebert-Chatelain E, Bellocchio L, Cathala A, Bari A, Serrat R, Finlay DB, Caraci F, Redon B, Martín-García E, Busquets-Garcia A, Matias I, Levin FR, Felpin FX, Simon N, Cota D, Spampinato U, Maldonado R, Shaham Y, Glass M, Thomsen LL, Mengel H, Marsicano G, Monlezun S, Revest JM, Piazza PV (2023) Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. https://doi.org/10.1038/s41591-023-02381-w |
